Paul M. Vanhoutte Distinguished Lectureship in Vascular Pharmacology

Paul M. Vanhoutte Distinguished Lectureship in Vascular Pharmacology

Deadline for submission of nominations for the 2010 Paul M. Vanhoutte Distinguished Lectureship in Vascular Pharmacology is September 15, 2009

The Paul M. Vanhoutte Award in Vascular Pharmacology was established to honor Dr. Vanhoutte’s lifelong scientific contributions to our better understanding and appreciation of the importance of endothelial cells and vascular smooth muscle function in health and disease and for his mentoring of countless prominent endothelial and vascular biologists and pharmacologists.

The Paul M. Vanhoutte Award is a biennial award, consisting an honorarium of $1,000, a custom-designed crystal bowl depicting the named Lectureship, and up to $2,000 travel expenses including registration to the annual spring ASPET meeting. A recipient will be selected and invited to deliver a state-of-the-art lecture on recent advances in vascular biology and pharmacology at the spring ASPET meeting (Division’s programming session). The presentation of his/her research should be of broad interest and contribute to the growth of the Cardiovascular Pharmacology Division.

There are no restrictions on institutional affiliation, nationality, or age of the candidate, but the recipient must be a member of the ASPET. Nominations must be made by a member of the ASPET, and no member may nominate more than one candidate per year. Final selection of the recipient will be made by the Award Committee of the Division for Cardiovascular Pharmacology.

Nominations should consist of not more than five letters from nominators describing the contributions to vascular biology and pharmacology of the candidate that make him/her eligible for this Award and listing of his/her major contributions, together with a complete curriculum vitae. To ensure consideration, all information must be submitted electronically to: Margie Arkin (markin@aspet.org), American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995 no later than September 15, 2009.